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Abstract Patients with multiple myeloma develop a dev-
astating bone disease driven by the uncoupling of bone
remodelling, excess osteoclastic bone resorption and
diminished osteoblastic bone formation. The bone pheno-
type is typified by focal osteolytic lesions leading to
pathological fractures, hypercalcaemia and other catas-
trophic bone events such as spinal cord compression. This
causes bone pain, impaired functional status, decreased
quality of life and increased mortality. Early in the disease,
malignant plasma cells occupy a niche environment that
encompasses their interaction with other key cellular
components of the bone marrow microenvironment.
Through these interactions, osteoclast-activating factors
and osteoblast inhibitory factors are produced, which
together uncouple the dynamic process of bone remod-
elling, leading to net bone loss and focal osteolytic lesions.
Current management includes antiresorptive therapies, i.e.
bisphosphonates, palliative support and orthopaedic inter-
ventions. Bisphosphonates are the mainstay of treatment
for myeloma bone disease (MBD), but are only partially
effective and do have some significant disadvantages; for
example, they do not lead to the repair of existing bone
destruction. Thus, newer agents to prevent bone destruction
and also promote bone formation and repair existing
lesions are warranted. This review summarises novel ways
that MBD is being therapeutically targeted.
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Introduction
Myeloma bone disease (MBD) is a hallmark feature of
multiple myeloma (MM). MM is a cancer of differentiated
B lymphocytes, known as plasma cells, involving their
clonal proliferation in the bone marrow. It is characterised
by the production of monoclonal immunoglobulins (known
as a paraprotein, monoclone or M-spike) and by the
uncoupling of the dynamic process of bone remodelling
[1]. MM accounts for 1% of new cancers worldwide, is the
second most common haematological malignancy and has
a 5-year survival rate of 49% [2, 3].
MM is a debilitating disease with features including
hypercalcaemia, renal impairment, anaemia and bone dis-
ease (summarised in the mnemonic CRAB) [4]. In MM,
80–90% of patients develop MBD (Fig. 1), leading to
pathological fractures, spinal cord compression and pain,
collectively referred to as skeletal-related events (SREs),
which contribute to a reduced quality of life [5]. Although
there has been a substantial increase in overall survival
(OS) in the past 10 years, 85% of osteolytic lesions develop
during management, which highlights a key pitfall in the
current management MBD [6, 7].
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MBD occurs due to the interactions between malignant
plasma cells (MPCs) and cells in the bone marrow
microenvironment (BMME), leading to accelerated overall
bone loss and the formation of focal osteolytic lesions.
Normal bone modelling is dysregulated leading to the
uncoupling of osteoclast and osteoblast activity, excessive
osteoclastic bone resorption and substantially reduced
osteoblastic bone formation [1, 3]. Furthermore, anti-MM
treatments, such as dexamethasone, can induce further
bone loss, potentiating MBD. Current treatments aim to
prevent further myeloma-induced bone disease through the
use of antiresorptive therapy. Recently, a number of
potential bone anabolic agents have been assessed in pre-
clinical models of MM and other novel agents are being
developed as our understanding of MBD improves [8–10].
This review focuses on current and novel agents that
specifically target MBD.
Pathophysiology of Myeloma Bone Disease
Under normal physiological conditions, osteoblasts and
osteoclasts work effectively in unison to remodel bone via
bone formation and bone resorption, respectively [1, 5].
Over the course of 7 years, the entire skeleton can be
remineralised and adapt to physiological stress due to the
opposing actions of osteoblasts and osteoclasts [5].
Osteoclasts and osteoblasts are the main cells involved in
bone modelling; however, this process is facilitated by
osteocytes, cytokines and hormones [1].
Osteoclasts originate from monocytes and digest the
bone matrix through the secretion of enzymes [11].
Osteoblasts differentiate from mesenchymal stem cells and
create the bone matrix through the secretion of collagen
[12]. Furthermore, immature osteoblasts secrete cytokines
such as interleukin-6 (IL-6) to upregulate osteoclasts and
mature osteoblasts secrete osteoprotegerin (OPG) to inhibit
the activation of osteoclasts [4, 13]. As new bone is
formed, osteoblasts become trapped and differentiate into
osteocytes [11]. Osteocytes contribute factors, such as
sclerostin, to both osteoclastogenesis and osteoblastogen-
esis to control bone remodelling.
MPCs cause the uncoupling of this bone remodelling
process by interacting with the BMME and stromal com-
ponents to induce osteoclast-activating factors (OAFs), first
described by Mundy et al., to promote osteoclastogenesis
[6, 14]. In the initial stages of the disease, both osteoblasts
and osteoclasts are recruited to initiate bone resorption.
Myeloma cells produce IL-1 and TNF, which stimulate
osteoblast progenitor cells to differentiate into osteoblasts,
thus recruiting more osteoblasts to the site. Osteoblasts
secrete IL-6, which is a potent myeloma growth factor and
promoter of osteoclastogenesis [4, 15].
However, once MBD is established, osteoblasts decrease
in number [15]. The mechanism that initiates this still
remains unclear; however, this possibly is achieved
through the release of osteoblast inhibitory factors (OBIs),
as described by Bataille et al. [4, 16]. Along with inhibiting
bone formation, a further reason osteoblasts are hypothe-
sised to be inhibited is due to decorin, a small leucine-rich
proteoglycan, which is produced by osteoblasts. Li et al.
[17] demonstrated that decorin has an anti-myeloma effect
through inhibiting transforming growth factor beta (TGF-
b) and decreasing tumour growth. However, there is con-
flicting evidence as to whether decorin is related to the
development of osteolytic lesions [18, 19]. Furthermore,
myeloma cells induce aberrant changes in osteoprogeni-
tors, through alterations in microRNA, which prevents their
Fig. 1 X-ray examples of
serious but
preventable myeloma-induced
osteolytic lesions and
pathological fractures
potentially preventable if
detected earlier. a Normal skull.
b Myeloma ‘pepper pot skull’
riddles with lytic lesions. c,
d Pathological fractures through
lytic lesions in the distal shaft of
the left humerus. e Pathological
fracture through the proximal
shaft of the left femur
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differentiation to osteoblasts, thus reducing the number of
osteoblasts further [20]. With the suppression of
osteoblastogenesis and the hyperactivation of osteoclasts,
the formation of osteolytic lesions expands from a singular
site (Fig. 2), to invade the entire bone marrow and destroy
the surrounding bone, eventually spreading into the blood
and metastasising to other bone sites [11].
Osteoclastic Bone Resorption is Increased
in Myeloma
The balance between osteoblasts and osteoclasts is main-
tained through the ratio of OPG:receptor activator of
nuclear factor kappa B (RANK) [21]. RANK and its ligand
(RANKL) activate the downstream nuclear factor kappa B
(NF-kB), which subsequently activates osteoclast precur-
sors and causes their differentiation to mature osteoclasts,
whilst simultaneously decreasing osteoclast apoptosis
[3, 6]. OPG is a soluble decoy receptor that inhibits RANK
via mimicking RANKL, in order to increase osteoblast
activity and promote bone formation [5, 6, 22].
Increased bone resorption is achieved through the
uncoupling of OPG:RANK:RANKL and an increased
production of RANKL [23]. MPCs adhere to bone marrow
stromal cells (BMSCs), which increases the production of
OAFs, such as RANKL, IL-6 and Activin A [1]. IL-6 is a
cytokine that is highly elevated in MM and shown to
correlate with increased bone destruction [24]. BMSCs and
macrophages are the main sources of IL-6, promote
osteoclastogenesis, increase MPC population and prevent
apoptosis through the induction of the P13k/AKT pathways
allowing proliferation and survival of MPCs [3, 5, 25].
Macrophage inflammatory protein-1 alpha (MIP-1a) is
secreted by MPCs and causes osteoclastogenesis through
binding to chemokine receptor type 1 (CCR1) and che-
mokine receptor type 5 (CCR5) on osteoclasts [3, 26].
Simultaneously, they improve the adhesion between MPCs
and BMSCs, therefore promoting a further increased pro-
duction of IL-6 and RANKL. Finally, MPCs create a
feedback loop, to ensure their own survival by producing
MIP-1a, which induces pathways such as mitogen-acti-
vated protein (MAPK) pathway [5].
Fig. 2 3D reconstructions of
computerised tomography (CT)
images using standard
diagnostic settings
demonstrating two patients with
widespread myeloma-induced
bone disease, leading to
potential serious consequences.
a Lytic lesion penetrating
through the ischium (green
arrow). b Multiple lytic lesions
throughout the scapula (green
arrows) with the acromion
completely destroyed by
myeloma bone disease (red
arrow). c Example of normal
bone from the shoulder, clavicle
and ribs. d Contrast image of
the patient riddled with lytic
lesions due to myeloma bone
disease. The acromion process
is destroyed (red arrow),
multiple lytic lesions are present
throughout the clavicle (green
arrow) and the anterior ribs have
been destroyed (purple arrow)
(Color figure online)
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OAFs that are elevated in MM patients include IL-3,
which increases osteoclast activity in combination with
RANKL and MIP-1a and synergistically works with IL-6
to promote MPC growth [1, 27]. Vascular endothelial
growth factor (VEGF), a signalling protein, and osteo-
pontin, a non-collagenous protein, are increased in MM
and both increase angiogenesis and osteoclastogenesis
[1, 14, 23]. Tanaka et al. demonstrated that when both
VEGF and osteopontin were inhibited, angiogenesis and
bone resorption were significantly reduced, highlighting
their potential role in MBD [28].
Inhibition of Osteoblastic Bone Formation is seen
in Myeloma
MBD is enhanced further by osteoblastic inhibition,
resulting in bone loss with no repair. A key pathway linked
to osteoblast differentiation, highlighted by Day et al. [12],
is the canonical Wnt pathway. b-Catenin, the downstream
product of the Wnt pathway is a potent promoter of OPG
and osteoblastogenesis [29]. Wnt proteins bind to a cell
surface receptor complex consisting of Frizzled and
lipoprotein-related (Lrp) 5/6 proteins [5]. This activates a
downstream cascade, which prevents the degradation of b-
catenin.
Levels of dickkopf-1 (Dkk-1) produced by both BMSCs
and MPCs are increased in the serum and the bone marrow
milieu of MM patients inhibiting the Wnt pathway,
resulting in a decrease in osteoblastogenesis [9, 26, 30].
Dkk-1 further inhibits immature osteoblasts to enable the
maximum amount of IL-6 to be secreted [13]. Secreted
frizzled-related protein 2 (sFRP-2), a further Wnt antago-
nist, preventing the binding of Wnt to Frizzled, is found to
be overexpressed in MM patients [5].
The transcription factor runt-related transcription factor
2 (Runx2)/core-binding factor runt domain alpha subunit 1
(CBFA1) is a key driver in osteoblast differentiation [31].
Runx2/CBFA1 works together along with other transcrip-
tion factors such as osterix to induce bone formation [32].
MPCs have the ability to inhibit Runx2/CBF1A, therefore
downregulating the differentiation of osteoblast from
osteoprogenitor cells and causing an increase in osteolytic
lesions [1, 33]. Furthermore, Runx2/CBFA1 mediates the
secretion of OPG and, therefore, upon inhibition decreases
OPG and increases osteoclastogenesis [33].
Development of osteolytic lesions is stimulated further
by a vicious cycle involving several other factors. TGF-b is
produced by the bone matrix during bone resorption and
inhibits osteoblast differentiation [3]. OAFs such as IL-3
and IL-7 play a dual role, by also inhibiting osteoblasts via
inducing Activin A and suppressing Runx2, respectively
[34]. Furthermore, MPCs secrete hepatocyte growth factor
(HGF), which inhibits bone morphogenetic proteins
(BMPs) and suppresses runx2, therefore inhibiting
osteoblastogenesis [35].
Tumour necrosis factor a (TNF-a) also plays a dual role
in both osteoclastogenesis and inhibition of osteoblast
differentiation. MPCs induce high levels of TNF-a in the
marrow microenvironment [36]. TNF-a increases BMSC
production of OAFs such as RANKL and IL-6 through
increasing the transcription factor spliced X-box binding
protein 1, thus increasing osteoclastogenesis [37]. TNF-a
inhibits osteoblast differentiation by decreasing runx2 and
osterix, which are key regulators in osteoblast differentia-
tion [38]. Furthermore, TNF-a can induce apoptosis of
mature osteoblasts [39]. Thus, the development of MBD
correlates directly to the stimulation of osteoclasts and
inhibition of osteoblasts (Fig. 3).
Furthermore, anti-MM treatment can exacerbate bone
loss and contribute to MBD [40]. High-dose steroids such
as dexamethasone and prednisolone are commonly used in
MM, to reduce inflammation, improve the patients’
immune system and reduce the side effects of chemother-
apy [41]. Steroids inhibit IL-6 and reduce NF-kB, inducing
apoptosis in MPCs, and thus provide a backbone to many
MM treatment regimes [42]. However, high-dose dexam-
ethasone is also known to inhibit osteoblastogenesis,
downregulate OPG and in turn upregulate the interaction
between RANK and RANKL, thus promoting osteoclas-
togenesis and bone resorption [41]. This highlights the
clinical challenge of prescribing a dose of high-dose ster-
oids that positively impacts MM but without causing pro-
gression of MBD. In recent studies, combining steroids
such as dexamethasone with immunomodulatory drugs and
bisphosphonates (inhibit bone resorption) has reduced the
extent of the bone loss caused by high-dose steroids [43].
Osteocytes Regulate Bone Remodelling in MBD
Osteocytes are the most abundant bone cells, making up
95% of all bone cells [44]. Osteocytes contribute to the
vicious cycle of MBD by regulating bone remodelling
through releasing paracrine factors, such as sclerostin and
RANKL that affect osteoblasts and osteoclasts, respec-
tively. Giuliani et al. demonstrated that MM patients with
MBD had fewer osteocytes than healthy controls, indicat-
ing that osteocyte apoptosis may play a role in the devel-
opment of osteolytic lesions [45]. Osteocyte apoptosis is
accompanied by increases in RANKL, therefore promoting
osteoclast differentiation and regulating bone resorption
[45]. Furthermore, MPCs caused the upregulation of OAF
IL-11 from osteocytes, promoting osteoclast differentiation
[34].
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Osteocytes secrete Dkk-1 and sclerostin, a potent inhi-
bitor of bone formation [30]. Sclerostin inhibits the
canonical Wnt pathway, therefore downregulating the
production of Wnt target genes, such as OPG, and
increasing the RANKL/OPG ratio, leading to an inhibition
in osteoblast differentiation and bone formation [46].
Furthermore, osteocytes are able to create a network of
interactions from cell-to-cell contact between each other to
cells on the cell surface and are able to distribute cytokines
throughout the bone marrow, thus making osteocytes the
central regulators of bone homeostasis and highlighting
how osteocytes may therefore play an important role in the
development of MBD [44].
Current Treatment of MBD
Once MM has been diagnosed and MBD is detected, var-
ious treatments are available. A multidisciplinary approach
is needed to ensure that a patient’s quality of life is
maintained through the use of analgesia for pain, surgery or
radiotherapy for MBD. MBD will progress without ade-
quate anti-MM treatment, and thus a patient management
plan needs to treat the underlying MM through the use of
anti-MM treatment and combine this with MBD treatment.
Preventative therapies are needed to delay disease pro-
gression in MBD, with the mainstay of treatment being
antiresorptive agents. Bisphosphonates are the only treat-
ment licensed for the prevention of MBD worldwide.
However, they do not completely prevent osteolytic lesions
and fail to promote new bone formation or repair of
existing lesions [47]. Recently, novel anabolic agents such
as anti-sclerostin and anti-Dkk1, which promote
osteoblastogenesis and bone formation and have the
potential to repair existing lesions, have been developed,
which may lead to a substantial improvement of MBD
(Fig. 4) [9, 10, 30].
Antiresorptive Therapies
Bisphosphonates (BPs)
The initial first-line treatment for MBD is antiresorptive
therapies, such as BPs. These originate from a key obser-
vation made by Fleisch and Neuman that body fluids, such
as urine, contain natural inhibitors of calcification [48].
This compound was found to be inorganic pyrophosphate
Fig. 3 Pathophysiology of MBD. The uncoupling of osteoclasts and
osteoblasts is stimulated by the release of osteoclast-activating factors
(OAFs) and osteoblast inhibitory factors (OBIs). These factors are
released by the adhesion of bone marrow stromal cells (BMSCs) to
myeloma cells causing upregulation of osteoclast and bone resorption,
whilst simultaneously inhibiting osteoblasts and bone formation.
Osteocytes also play an important role by releasing sclerostin, which
inhibits osteoblast differentiation and increases bone marrow adipose
tissue (BMAT). Dkk-1 dickkopf-1, sFRP-2 secreted frizzled-related
protein 2, IL-7 interleukin-7, IL-3 interleukin-3, HGF hepatocyte
growth factor, Runx2 runt-related transcription factor 2, CBFA core-
binding factor alpha, BMP-2 bone morphogenetic protein 2, RANK
receptor activator of nuclear factor kappa B, RANKL receptor
activator of nuclear factor kappa B ligand, IL-6 interleukin-6, MIP-
1a macrophage inflammatory protein-1 alpha, OPG osteoprotegerin,
TGF-b transforming growth factor beta, TNF-a tumour necrosis factor
alpha
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(PPi). Further studies revealed that high levels of PPi cause
defective skeletal mineralisation, whilst low levels caused
excessive mineralisation and bone formation [49]. This led
to the development of different PPi analogues to inhibit
abnormal calcification, eventually producing BP analogues
(P–C–P motif). Although initially used to prevent calcifi-
cation of soft tissues, BPs were soon discovered to inhibit
bone resorption, thus marking the beginning of the era of
their use as antiresorptives [50, 51].
Non-nitrogen-containing BPs, such as clodronate, are
thought to induce apoptosis of osteoclasts by causing the
accumulation of non-hydrolyzable ATP analogues [52].
Nitrogen-containing BPs, such as pamidronate and zole-
dronic acid, bind to hydroxyapatite and then cause osteo-
clast apoptosis via inhibition of the mevalonate pathway
via the enzyme farnesyl diphosphate synthase [1, 53, 54].
The nitrogen-containing BPs, such as zoledronic acid,
have proved to be significantly superior at decreasing SREs
than the non-nitrogen-containing BPs, such as clodronate,
which was highlighted in the MRC Myeloma IX trial [47].
A subset analysis of the MRC Myeloma IX trial also
demonstrated a significant reduction in tumour burden in
patients receiving zoledronic acid compared to patients
receiving clodronate. Although the mechanism of this
antitumour effect is uncertain, this finding has provided
strong additional rationale for the use of zoledronic acid
rather than clodronate in the treatment of patients with
MM. Comparatively, the choice for zoledronic acid to be
used as the first-line treatment instead of pamidronate is
also due to reduced infusion time and reduction in other
adverse events [54–56].
Despite BPs being the initial treatment of choice, the
longevity of their use is limited due to their side effects.
These include renal toxicity requiring dose reduction in
patients with renal impairment, flu-like symptoms and
gastrointestinal upset during administration, atrial fibrilla-
tion, atypical femoral fracture and osteonecrosis of the jaw
(ONJ), which can occur in 3.5% of patients [47]. Although
inferior, nitrogen-containing BPs, such as clodronate,
exhibit a lower rate of ONJ compared to zoledronic acid (1
vs. 4%, respectively) [47]. Furthermore, pamidronate can
be administered to patients with significant renal impair-
ment [57]. Due to these risks, BPs are recommended for up
Fig. 4 MBD treatments and their interactions in the BMME. MBD
treatments use multiple different mechanisms in order to reduce bone
resorption and increase bone formation to repair osteolytic lesions. A
plethora of treatments are currently in trials; however, a combination
of both anabolic and antiresorptive methods appears to have the most
potential for healing MBD. RANKL receptor activator of nuclear
factor kappa B ligand, RANK receptor activator of nuclear factor
kappa B, PIs proteasome inhibitors, IMiDs immunomodulatory
agents, OC osteoclast, Scl-ab anti-sclerostin antibody, Dkk-1 dick-
kopf-1, sFRP-2 secreted frizzled-related protein 2, IL-7 interleukin-7,
IL-3 interleukin-3, HGF hepatocyte growth factor, Runx2 runt-related
transcription factor 2, TGF-b transforming growth factor beta, NF-kB
nuclear factor kappa B, BMSCs bone marrow stromal cells, BMAT
bone marrow adipose tissue, OBIs osteoblast inhibitory factors, OAFs
osteoblast-activating factors
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to 2 years before a break in treatment and the continuation
to be administered at much longer intervals.
Denosumab
Denosumab is an anti-RANKL monoclonal antibody,
designed to prevent osteoclast function and osteoclastoge-
nesis by preventing the RANK–RANKL interaction [5].
Denosumab thus mimics OPG by decreasing the amount of
RANKL available. Currently, denosumab is not approved
for use in MM. However, there is an ongoing clinical trial
(NCT00330759) comparing denosumab to zoledronic acid
in MM patients, the preliminary results of which show that
denosumab has similar results for time to future skeletal
events, but has significantly lower renal toxicities com-
pared to zoledronic acid (10 vs. 17.1%) [58].
Although there are limited studies primarily aimed at
denosumab and MM, those that have reported data have
concluded that denosumab is non-inferior to zoledronic
acid. Henry et al. [59] showed no significant difference
between the two arms in regards to delaying first onset
SRE, OS and progression-free survival (PFS). However,
denosumab did exhibit higher rates of hypocalcaemia and
similar levels of ONJ, but had potentially higher mortality
rates. This study did conclude that MM needed to be
investigated further as their results were for a variety of
cancers and that there was a possible variant in hetero-
geneity of the population used.
Raje et al. [60] found similar findings in a subset of MM
patients and concluded that denosumab was non-inferior.
However, they did raise the concern of a higher mortality
in the denosumab arm compared to zoledronic acid (22 vs.
9%). This study had a number of confounding factors
including a small subgroup of patients from a larger trial
and a large amount of withdrawals with no follow-up
which may have skewed the results towards zoledronic
acid.
Denosumab is recommended when BPs cannot be pre-
scribed, for example due to renal toxicities. There is also a
recommendation to use denosumab if hypercalcaemia of
malignancy occurs and is refractory to BPs [61]. Deno-
sumab is not nephrotoxic and can be given as a subcuta-
neous injection, which allows easier access for patients to
this treatment and provides a potential alternative to those
that cannot have BPs.
Anabolic Agents
Parathyroid Hormone
Parathyroid hormone (PTH) has been shown to have ana-
bolic affects in bone remodelling in osteoporosis. At high
levels, PTH causes an increase in bone resorption due the
release of calcium from the bone initiated by PTH [62, 63].
However, intermittent doses have been shown to be ana-
bolic in nature rather than resorptive. Teriparatide, a
recombinant form of PTH, has been approved for use in
women with osteoporosis [64]. The mechanism for teri-
paratide’s anabolic effect is unclear, but it is thought to be
due to PTH having a direct effect on osteoblasts, therefore
increasing osteoblastogenesis and also inhibiting sclerostin,
a potent promoter of osteoclastogenesis [62].
Pennisi et al. [65] studied PTH administration in mouse
models for MM and showed that there was an increase in
bone mineral density via the upregulation of osteoblasts,
although this was not seen in vitro. However, the myeloma
cell line that was used did not express PTH receptors. In
addition, teriparatide has been shown to improve bisphos-
phate-associated ONJ after alendronate was stopped, by
showing significant healing of necrotic bone in various
patient case reports, showing a potential therapeutic use in
combination with BPs [66].
However, in contradicting studies, high levels of PTH
may be a potential risk factor for MM. Kang et al. [63]
demonstrated that high PTH levels may facilitate the
growth of myeloma cells via secretion of IL-6 and that
higher PTH levels at diagnosis correlated with a poorer
PFS but no difference in OS. Furthermore, in certain can-
cers such as prostate cancer, PTH may increase metastases
[67]. The safety and efficacy of PTH in MM are therefore
still to be established, but warrant further enquiry given
promising results obtained in patients with osteoporosis.
Anti-Dkk-1
Dkk-1 is a potent regulator of the Wnt signalling pathway
and inhibits the Frizzled co-receptor LRP6 [68]. Dkk-1 is
produced by BMSCs and MPCs and it has been found to be
elevated in MM patients. Dkk-1, along with sclerostin,
decreases the levels of b-catenin, which in turn reduces
osteoblast differentiation [69]. If osteoblasts cannot repair
the osteolytic lesions, even with the use of antiresorptive
agents to prevent bone resorption, MBD will persist.
Tian et al. [9] first hypothesised that there is an increase
in Dkk-1 in MPCs and the bone marrow of MM patients.
They showed that Dkk-1 inhibits the differentiation of
osteoblasts and increases the activity of osteoclasts via
increased expression of RANKL from osteocytes. This
study used patients with varying penetrance of MM,
demonstrating an increase in Dkk-1 in those with active
MBD, as well as those without osteolytic lesions.
Anti-Dkk-1 agents have been investigated as a novel
target, including the agent BHQ880, a humanised IgG anti-
Dkk-1 monoclonal antibody. In vitro and in vivo analyses
of the effects of BHQ880 were highlighted by Fulciniti
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et al. [24], showing that BHQ880 was successful at
inhibiting Dkk-1 and increasing osteoblast differentiation
and activity, as shown by the increase in trabecular thick-
ness. BHQ880 activity in vivo was analysed by H&E
staining of the bone to highlight the amount of myeloma
cells and was monitored by IL-6 murine blood levels,
which are produced from BMSCs and decrease when these
differentiate into osteoblasts, indicating that a higher level
of IL-6 correlates with a decrease in osteoblast differenti-
ation. However, a limitation of this method is that IL-6 is
not just produced by myeloma cells so this may not be the
most accurate way to monitor BHQ880 activity.
Finally, they concluded an unknown effect of BHQ880
on osteoclastogenesis, implying that this would be used as
a combination treatment with antiresorptive agents. A
limitation of this study was that only one cell line was used
in the in vivo models, which may not be representative of
MM.
A phase 1b multicentre study has been undertaken by
Iyer et al. [70], which combined BHQ880 with zoledronic
acid and an anti-myeloma treatment regimen. They repor-
ted that this combination was well tolerated by MM
patients and caused a delay in SREs whilst increasing bone
density. However, these results are from the combined
treatment, making it unclear how much BHQ880 had an
independent effect on these outcomes.
A further mechanism for anti-Dkk-1 treatment that has
recently been highlighted is through the interaction of Dkk-
1 and microRNA (mi-RNA). Mi-RNA contributes to cell
proliferation, apoptosis and differentiation, and the down-
regulation of several mi-RNA can lead to tumour pro-
gression. Xu et al. [71] demonstrated that mi-RNA152
directly targeted Dkk-1 and reduced the expression of Dkk-
1. Mice were injected into the femur with myeloma cells
(MM.1S) that were infected with mi-RNA152. This caused
an elevation in mi-RNA152, which sequentially decreased
the expression of Dkk-1, resulting in decreased bone
destruction and increased bone mineralisation. Limitations
of this study include using only one cell line for analysing
osteolytic lesions and that by manipulating mi-RNA this
could lead to unwanted systemic effects.
A phase II clinical trial has been completed
(NCT01337752), which evaluates the use of BHQ880
when BPs are contradicted due to renal insufficiency. The
results of this trial are yet to be published, however once
available these results may highlight BHQ880 use in MM.
However, anti-Dkk-1 treatment still needs thorough
investigation to determine its optimal use in MBD. A
concern with this treatment is that some patients do not
have increased levels of Dkk-1 and in end-stage disease
Dkk-1 decreases [9]. This may be due to the increased
interaction of MPCs with osteoclasts or due to a mutation
in p53 which is strongly associated with Dkk-1. However,
follow-up research would be needed to ensure that
inhibiting Dkk-1 did not advance the disease [11].
Anti-sclerostin
Sclerostin, encoded by the SOST gene, is produced by
osteocytes, binds to Wnt co-receptors LRP5/6 and antag-
onises the pathway [72]. Sclerostin has been shown to be
an important mechanism in osteoporosis; however, its
importance has not been established in MBD [69].
Romosozumab, a humanised monoclonal anti-sclerostin
antibody, has been approved in osteoporosis, shows
marked improvement in bone formation and bone mineral
density, whilst decreasing bone resorption markers, and
could be a potential agent for MBD [73]. However, Amgen
have recently released a statement regarding their ARCH
study that romosozumab increases a patient’s cardiovas-
cular risk by 2.5% compared to alendronate (1.9%), caus-
ing the European Medicine Agency to rule that
romosozumab be used only in patients with no history of
cardiac problems.
MM upregulates SOST and increases the expression of
sclerostin from osteocytes. Delgado-Calle et al. [74]
showed in mice with MM a raised level of sclerostin and a
decrease in OPG of 50%. This correlated with a decrease in
osteoblast markers, providing evidence for a link between
the inhibition of the Wnt signalling pathway and osteoblast
differentiation in the presence of raised sclerostin.
Reagan et al. [10] demonstrated in vivo that anti-scle-
rostin treatment delivered to MM-bearing mice was
effective in increasing trabecular bone volumes by 46%
and trabecular thickness by 30%, returning their bone
volumes to similar levels of the non-tumour control mice
and prevented further MBD. Two cell lines were used in
this study, both exhibiting a positive effect, demonstrating
the heterogeneity of anti-sclerostin treatment. Although
mice with different immunodeficiency status were used for
the two different cell lines, which may have contributed to
the different results obtained, this work has now been
further developed into three myeloma cell lines, which
demonstrated that sclerostin is an osteocyte-specific protein
and not released by myeloma cells [30]. Treatment of the
myeloma-bearing mice in all three cell lines with an anti-
sclerostin antibody caused an increase in osteoblastogene-
sis, reduced the development of osteolytic lesions and
prevented myeloma-induced bone loss whilst increasing
bone strength. Bone resorption was not prevented; how-
ever, combining anti-sclerostin treatment with the bispho-
sphonate, zoledronic acid, significantly improved bone
strength compared to either treatment alone.
Eda et al. [69] further confirmed that mice injected with
MM had higher levels of sclerostin and hypothesised that
the decrease in b-catenin levels was the result of this.
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When treated with anti-sclerostin (scl-ab), trabecular bone
thickness and volume increased in these mice. Also
demonstrated was a potential link that Dkk-1 mediates the
increase in sclerostin via inducing its release from
osteoblasts.
Scl-ab has recently been shown to reduce bone marrow
adipose tissue (BMAT) [75]. BMAT creates an optimal
environment for MM by secreting growth factors such as
IL-6, signalling molecules such as adipokines and fatty
acids, creating an energy source and endocrine secretions
that optimise MPCs’ growth and induce osteolytic lesions
[75, 76]. BMAT differentiation is regulated by sclerostin,
which inhibits Wnt signalling in pre-adipocytes and pro-
motes adipogenesis [77]. Thus, inhibiting sclerostin redu-
ces BMAT differentiation and increases bone formation.
Sclerostin is a promising target and its inhibition has
been shown to be beneficial in postmenopausal women and
osteoporosis; however, currently there are no clinical trials
for MM [73, 78]. The potential for a dual target with Dkk-1
may also be a promising therapeutic in the future [72].
Transforming Growth Factor Beta (TGF-b)
TGF-b is part of the TGF-b superfamily and has been
implicated in various cancers for tumour-induced bone
disease [6]. MBD causes an increased release of TGF-b by
osteoclasts; however, the mechanism of TGF-b tumour-
induced bone disease is unknown. A potential mechanism
outlined by Balooch et al. [79] is that TGF-b activates
SMAD3, which in turn binds to osteoblast promoters such
as the transcription factor Runx2, sequentially suppressing
the transcription of genes involved in osteoblast
differentiation.
Nyman et al. [8] investigated the use of TGF-b inhibitor
neutralising antibody (1D11) in myeloma-bearing mice.
This improved the bone disease in mice and increased
osteoblast differentiation. However, there was no
improvement of overall tumour burden in these mice.
There were differing results between the cell lines, which
remain unexplained, and the long-term side effects were
not explored such as widespread inflammation or cardio-
vascular defects, which would be an important result to
establish in this treatment [80]. This is due to the dual
action of TGF-b, as TGF-b can act as both an oncogene
and a tumour suppressor [81]. Inhibiting the tumour-sup-
pressing action of TGF-b may induce these side effects;
however, these have yet to be confirmed in clinical trials
[80].
Lu et al. [82] inhibited a different mechanism of TGF-b
tumour-induced bone disease, which involves Throm-
bospondin1 (TSP-1). TSP-1 activates latent TGF-b that has
been deposited by MPCs. A TGF-b inhibitor, SRI31277,
was administered to mice with highly osteolytic lesions
(human CAG-hpse cell lines) and showed a decrease in
tumour burden and a decrease in phosphorylated SMAD2,
which was associated with a decrease in osteoclasts and an
increase in osteoblastogenesis. There were no noted side
effects, which if translated into patients would be valuable.
However, osteolytic lesions were only examined in one cell
line, questioning how representative this would be in MM.
Activin A and Sotatercept
Activin A is a member of the TGF-b superfamily alongside
BMPs. Activin A is released from osteoblasts and osteo-
clast precursors and has been shown to be elevated in
patients with MM. Oslen et al. [83] used in vitro models to
establish that both TGF-b and BMPs share 3 receptors:
activin receptor type 2A (ACVR2A), activin A receptor
type 2B (ACVR2B) and activin receptor-like kinase-2
(ALK2). BMPs induce MPC death via these receptors and
through activation of their downstream molecules SMAD
1/5/8. Activin A antagonises BMP-6 and BMP-9 by com-
peting for their receptors ACVR2A/ACVR2B/ALK2 and
therefore inhibit BMP-induced apoptosis of MPC [83, 84].
Furthermore, activin A activates RANK/RANKL to pro-
mote osteoclastogenesis and drives the process of oste-
olytic lesions.
Sotatercept is a soluble recombinant activin receptor
type IIA (ActRIIA) ligand fused to the human FC-IG
fragment and binds activin A/B plus members of the TGF-
b superfamily to disrupt downstream cascades. Abdulka-
dyrov et al. [84] demonstrated during a phase II ran-
domised control trial that sotatercept as an addition to
melphalan, prednisolone and thalidomide caused an ana-
bolic effect and increased the biomarker bone alkaline
phosphatase (bALP), indicating improved bone turnover.
There are many limitations to this study however,
including a small patient size with heavily weighted
numbers in the intervention group and unclear side effect
profile interactions between each drug and uncertainty if a
significant change was actually seen when using
sotatercept.
Currently, a clinical trial (NCT01562405) recruiting
patients for the use of sotatercept in combination with
lenalidomide or pomalidomide and dexamethasone is being
undertaken. However, at present the evidence for the use of
sotatercept is still to be determined.
Agents that Combine Antitumour Activity and Bone
Anabolic Effects
Proteasome inhibitors (PIs) inhibit the transcription factor
NF-kB, thus reducing RANKL-mediated osteoclast differ-
entiation, and also decrease the degradation of the NF-kB
inhibitor I-kB, therefore preventing NF-kB from activating
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IL-6 and antiapoptotic genes. PIs synergistically produce
an anabolic effect by increasing osteoblast differentiation
through the upregulation of BMP-2 and the transcription
factor Runx2 and reducing sclerostin levels [85, 86]. Ini-
tially, PIs have been used in combination with steroids,
such as dexamethasone, and immunomodulatory agents,
such as lenalidomide. Durie et al. [87] demonstrated an
anti-myeloma effect of using the PI bortezomib, with
15.7% of patients having a complete response when treated
with bortezomib compared to 8.4% of patients in the
control group (lenalidomide and dexamethasone). There
was an increase in adverse side effects when treated with
bortezomib, including 33% of patients developing neuro-
logical toxic effects compared to 11% of patients in the
control group.
Terpos et al. [86] have shown that bortezomib, even as a
monotherapy, has anabolic activity, promoting osteoblas-
togenesis and leading to increased bone formation and
bone mineral density in patients with relapsed/refractory
MM. Harnessing these effects coupled with the potent anti-
myeloma effects seen with proteasome inhibitors is a
promising strategy requiring further evaluation [87].
However, Sezer et al. investigated bortezomib consolida-
tion alone vs. observation alone on MM-related bone dis-
ease who had received frontline high-dose therapy and
autologous stem cell transplantation and found that there
was no difference between each group of patients [88].
However, there were multiple limitations to this study
including that patients may have had prior bortezomib
induction-based therapy, chemotherapy and BPs in
patients, which may have influenced bone mineral density
and bone metabolism markers.
Second-generation PIs such as carfilzomib have been
approved for use in the UK when two other treatment plans
have failed and has been shown to have a better side effect
profile in regards to neuropathies, but unfortunately has a
higher number of adverse effects in total, particularly in
relation to cardiac events [89]. In 2015, the FDA approved
the first oral PI, ixazomib, for those with refractory MM,
which has the potential to overcome resistance and, in
preclinical studies, has been shown to have a bone anabolic
effect [90]. Both ixazomib and carfilzomib demonstrate
bone anabolic effects similar to bortezomib and, coupled
with their anti-myeloma effects, could be promising ther-
apeutics [89, 90].
Epigenetic changes caused by MM play a role in MBD
and disease progression. MM induces repressive epigenetic
histone changes at the Runx2 locus by promoting the
transcriptional repressor growth independent factor 1
(GFI1), which binds to Runx2, recruits histone modifiers
such as histone deacetylase 1 (HDAC1) and suppresses
Runx2 which is required for osteoblast differentiation [91].
Importantly, the recruitment of histone modifiers, such as
HDAC1, is required to maintain the suppression of Runx2
[92]. Adamik et al. demonstrated that the inhibition of
HDAC1 reversed the repression of Runx2 and increased
osteoblast differentiation [92]. HDAC inhibitors (HDACi),
such as vorinostat, could act as both an anabolic agent by
increasing osteoblast differentiation and an anti-myeloma
agent. HDACi decrease cell proliferation through reducing
the viability of IL-6, induce cell cycle arrest at the G1/S
phase and induce apoptosis of MPC via upregulation of
both the intrinsic and extrinsic apoptotic pathways [93].
Although beyond the scope of this review, a plethora of
new agents have been developed that are predominantly
anti-myeloma chemotherapies but also have some positive
effects on the regulation of MBD. These include the
immunomodulatory compounds (thalidomide, lenalido-
mide, pomalidomide), monoclonal antibodies (daratu-
mumab, elotuzumab) and histone deacetylase inhibitors
(panobinostat) [1, 5]. There are also some novel agents in
clinical trials including a kinesin spindle protein inhibitor,
filanesib (Clinical Trial: NCT02384083), and an exportin 1
inhibitor, selinexor (Clinical Trial: NCT02336815), which
have some promising preliminary results.
Conclusion
MM survival outcomes and quality of life have dramati-
cally improved with the introduction of many new
encouraging agents. With patients surviving longer with
their disease, this therefore highlights the need to introduce
more effective agents for the treatment of MBD [7]. BPs
remain the mainstay of treatment for MBD. However, their
limited efficacy, inability to promote new bone formation
and concerns over their side effect profile demonstrate the
strong potential utility of bone anabolic agents. The
mounting evidence of the benefits being exhibited by bone
anabolic agents, such as anti-Dkk-1, anti-RANKL, anti-
sclerostin and anti-TGF-b, does bring promise to
improvements in the treatment of MBD.
However, further understanding of the multitude of
factors involved in the pathophysiology of MBD and the
complex interplay between MPCs and the BMME is
essential, to truly determine the efficacy of these agents and
their long-term outcomes.
With many agents in clinical trials and a plethora of
factors to target, combination treatment presents the most
potential for the management of MBD. The reduction in
bone resorption coupled with new bone formation is nec-
essary to decrease the burden of the disease. Bone anabolic
agents in combination with both antiresorptive agents and
anti-myeloma therapies may pave the way for future
treatment of MBD, but further research is warranted to
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validate these outcomes for patients and ultimately deter-
mine their quality of life and survival.
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